MEFDASE: Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study

Sponsor
University Hospital, Angers (Other)
Overall Status
Unknown status
CT.gov ID
NCT04288635
Collaborator
(none)
30
12

Study Details

Study Description

Brief Summary

Septic shock is defined as a subset of sepsis with severe metabolism alterations, leading to organ failure. Septic shock is associated with a high mortality, around 40% according to the SEPSIS 3 definition.

Metabolic alterations are responsible for lactic acidosis, and results in mitochondrial dysfunction.

This study aims at evaluate the impact of exogenous metabolites on restoring mitochondrial function in septic shock patients with lactate acidosis.

Mitochondrial metabolism (quantitative analysis, mitochondrial function) in intact Peripheral Blood Mononuclear Cells (PBMC) will be isolate and analyse from patients at the early phase of septic shock (admission), at day 2 and 4. Participant's medical history will be recorded: renal and liver metabolism, severity scores and outcomes and the need for supportive care in the intensive care unit (ICU) until 28 days after admission.

Furthermore, the investigators will evaluate wether selected metabolites added to the cell culture medium may improve mitochondrial metabolism.

Condition or Disease Intervention/Treatment Phase
  • Biological: Whole blood samples

Detailed Description

In this prospective study, the investigators will include patients admitted to the medical ICU of Angers University Hospital and meeting the SEPSIS-3 criteria for the definition of septic shock (Sequential Organ Failure Assessment (SOFA) score > 2, hyperlactatemia > 2 mmol/L and sepsis).

Blood samples will be collected during the usual care of initial resuscitation and analyzed in the laboratory INSERM (Institut national de la santé et de la recherche médicale) U1232 (University Hospital of Angers).

Mitochondrial metabolism will be analyzed in freshly isolated PBMC and after culture for 1-3 days, with or without the addition of selected metabolites to the cell culture medium.

The evolution of ketogenesis, mitochondrial function, acidobasic status will be assessed across the time (blood samples at day 2 and 4).

Survival, renal and liver metabolism, severity scores and outcomes and the need for supportive care in the intensive care unit (ICU) until 28 days after admission will be recorded.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study: MEFDASE Study
Anticipated Study Start Date :
Mar 1, 2020
Anticipated Primary Completion Date :
Dec 31, 2020
Anticipated Study Completion Date :
Mar 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Septic shock admitted in Angers' ICU

Patients aged more than 18, admitted in University Hospital of Angers, who meet the full criteria of septic shock

Biological: Whole blood samples
Whole blood samples at admission, from day one to three after admission

Outcome Measures

Primary Outcome Measures

  1. Change in mitochondrial metabolism (mitochondrial membrane depolarization and respiration) with the supplementation of metabolite in the cell culture medium [Day 0 (whole blood after cells separation), Day 1-3 after cell culture]

    Using Fluorescence-activated cell sorting system to assess the membrane depolarization of the mitochondria and Oroboros system for mitochondrial respiration

Secondary Outcome Measures

  1. Overall survival at 28 days [Day 28]

    Survival of patients after ICU admission

  2. Change in organs failure [From Day 0 to Day 4]

    Using the Sequential Organ Failure Assessment Score

  3. Change and correlation between lactic acidosis, ketogenesis and mitochondrial function evolutions [From Day 1 to Day 3]

    biochemical analysis of blood samples, assessment of mitochondrial metabolism (quantitative and qualitative analysis).

  4. Need for renal replacement therapy during the ICU stay [From Day 1 to Day 28]

    Need for renal replacement therapy and its duration

  5. Need for vasopressors during the ICU stay [From Day 1 to Day 28]

    Need for vasopressors during the ICU stay and its duration

  6. Need for mechanical ventilation during the ICU stay [From Day 1 to Day 28]

    Need for mechanical ventilation during the ICU stay and its duration

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patients aged 18 or more

  • Patients with criteria for septic shock according to SEPSIS 3 definition (presumed sepsis, with persisting hypotension requiring vasopressors to maintain mean arterial pressure > 65 mmHg and having a serum lactate > 2 mmol/L despite adequate fluid expansion).

  • Admitted in the ICU of Angers University Hospital

Exclusion Criteria:
  • Minor patients (aged less 18)

  • Patient subject to legal protection measures

  • Refusal of the patient or his family

  • Preexisting mitochondrial disease

  • Patient with aplasia

  • Pregnant or parturient women

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Angers

Investigators

  • Principal Investigator: Julien DEMISELLE, MD, University Hospital of Angers

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Angers
ClinicalTrials.gov Identifier:
NCT04288635
Other Study ID Numbers:
  • 49RC19_0189
First Posted:
Feb 28, 2020
Last Update Posted:
Feb 28, 2020
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Angers
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 28, 2020